期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

生物制剂治疗类风湿关节炎的研究进展 被引量：2

Progress of biological agents for treatment of rheumatoid arthritis
下载PDF
导出
摘要 类风湿关节炎(RA)是一类常见致残性自身免疫性疾病,传统的治疗药物主要有非甾体抗炎药、糖皮质激素等,但仍有部分病人病情无法控制,最终导致关节进行性破坏。近年来,多种生物制剂的出现为难治性RA的治疗带来了希望,可以有效控制风湿病活动和改善患者生活质量。该文就生物制剂在RA中的治疗进展作一综述。 Rheumatoid arthritis （RA） is a common disablihg autoimmune diseases. Traditional drugs treatment for RA include nonsteroid anti-inflammatory drugs,corticosteroids and so on. Lots of patients can＇ t get satisfied control for the condition of refractory RA,and result in severe joint damage. Biological agents have revolutionized the treatment of RA. These agents play an important role in the control of rheumatic conditions and the improvement of quality of life in RA patients.
作者 石宇红 谭毅
机构地区 桂林医学院附属医院风湿免疫科
出处 《中国临床新医学》 2012年第6期562-567,共6页 CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金 广西卫生厅科研课题(编号:Z2009044)
关键词 类风湿关节炎 生物制剂 治疗 Rheumatoid arthritis（RA） Biological agents Treatment
分类号 R593.22 [医药卫生—内科学]
  • 相关文献

参考文献26

  • 1Mohler KM,Torrance DS, Smith CA, et al. Soluble tumor necrosis fac- tor(TNF) receptors are effective therapeutic agents in lethal endotox- emia and ruction simultaneously as both TNF carriers and TNF antago- nists[ J ]. J lmmunol, 1993,151 (3) : 1548 - 1561.
  • 2Moreland LW ,Banmgarlner SW, Sohiff MH, et al. Treatment of rheu- matoid arthritis with a recombinant human tumor necrosis factor recep- tor(p75)-Fe fusion protein[J]. N Engl J Meal,1997,337(3) :141 - 147.
  • 3Moreland LW, Schiff MH, Baumgartner SW, et al. Etanereept therapy in rheumatoid arthritis. A randomized, controlled trial [ J ]. Ann Intern Med,1999,130(6) :478 -486.
  • 4Keremer JM ,Weinblatt ME,Bankhurst AD,et al. Etanereept added to the background methotrexate therapy in patients with rheumatoid ar- thritis : eontimued observation [ J ]. Arthritis Rheum, 2003,48 ( 6 ) : 1493 - 1499.
  • 5van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Com- parison of etanereept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial [ J ]. Aahritis Rheum,2006,54(4) :1063 - 1074. Siddiqui MA, Scott I.,1. Infliximab : a review of its use in Crehn' s dis- ease and rheumatoid arthritis [ J ]. Drugs, 2005,65 ( 15 ) : 2179 - 2208.
  • 6Siddiqui MA, Scott IJ. Infliximab : a review of its use in Crohn' s dis- ease and rheumatoid arthritis [ J ]. Drags, 2005,65 ( 15 ) : 2179 - 2208.
  • 7Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-a]pha biopharmaceuticals: assessing serum infliximab and anfi-infliximab antibodies [ J ]. Rheumatology ( Oxford ), 2007, 46 (12) :1828 - 1834.
  • 8Lipsky PE, van der Heijde DM, St Clair EW, et al. lnfliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Nec- rosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group[J]. N Engl J Med,2000,343 (22):1594-1602.
  • 9van Vollenhoven RF, Ernestam S ,Geborek P, et al. Addition of inflix- imab compared with addition of sulfasalazinc and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis( Swefot tri- M) : 1-year results of a randomised trial [ J ]. Lancet, 2009, 374 (9688) :459 -466.
  • 10Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody,for the treatment of rheumatiod arthritis in patients taking concomitant methotrexate:the ARMADA trial[J]. Arthritis Rheum,2003,48 ( 1 ) :35 - 45.

同被引文献12

引证文献2

二级引证文献13

中国临床新医学
2012年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部